A share price of Ionis Pharmaceuticals Inc [IONS] is currently trading at $34.76, up 1.91%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IONS shares have gain 4.32% over the last week, with a monthly amount glided 6.04%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on April 07, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $45. Previously, Redburn Atlantic started tracking the stock with Neutral rating on March 31, 2025, and set its price target to $39. On August 02, 2024, downgrade downgraded it’s rating to Market Perform and revised its price target to $60 on the stock. Leerink Partners upgraded its rating to a Outperform and increased its price target to $62 on July 24, 2024. Bernstein upgraded its rating to Mkt Perform for this stock on June 14, 2024, but kept the price target unchanged to $44. In a note dated April 10, 2024, Wolfe Research upgraded an Outperform rating on this stock but restated the target price of $58.
Ionis Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $23.95 and $52.34. Currently, Wall Street analysts expect the stock to reach $51.68 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $34.76 at the most recent close of the market. An investor can expect a potential return of 48.68% based on the average IONS price forecast.
Analyzing the IONS fundamentals
Trailing Twelve Months sales for Ionis Pharmaceuticals Inc [NASDAQ:IONS] were 717.68M which represents 10.14% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -0.66%, Pretax Profit Margin comes in at -0.65%, and Net Profit Margin reading is -0.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.92 and Total Capital is -0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.96.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.13 points at the first support level, and at 33.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.21, and for the 2nd resistance point, it is at 35.66.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ionis Pharmaceuticals Inc [NASDAQ:IONS] is 9.66. Further, the Quick Ratio stands at 9.62, while the Cash Ratio is 1.06. Considering the valuation of this stock, the price to sales ratio is 7.71, the price to book ratio is 11.62.
Transactions by insiders
Recent insider trading involved Hayden Michael R, Director, that happened on May 01 ’25 when 15000.0 shares were purchased. EVP, Corp and Development Ops, Birchler Brian completed a deal on Apr 16 ’25 to sell 680.0 shares. Meanwhile, EVP, Chf GL Pdt Str Ofcr Jenne Kyle sold 3016.0 shares on Apr 16 ’25.
